Netupitant / Palonosetron: 6 agencies, 2015–2023
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Assessment has run over 7.7 years, from 27 Nov 2015 at TLV (Sweden) to 2023 at PBAC (Australia).
AWMSG (Wales) changed its position: restricted on 27 Jul 2016, not recommended by 4 Aug 2020.
No assessment is on file from SMC (Scotland), PHARMAC (New Zealand) and CIPM (Spain), each among the eight highest-volume agencies here.
Against its own class, netupitant / palonosetron is an outlier: 67% of its decisive outcomes were positive, where molecules sharing ATC class A04A average 87%.
1 of these 8 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
TLV (Sweden) was first to assess netupitant / palonosetron, on 27 Nov 2015; PBAC (Australia) did not open a file until 2023 — a wide spread of 7.7 years between the earliest and latest system to look at it.
2 of the 6 agencies here assessed netupitant / palonosetron more than once, HAS (France) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for netupitant / palonosetron.
The full ledger for netupitant / palonosetron reads 3 recommended, 2 not recommended, 1 advice and 1 restricted, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2023 | Nausea and vomiting | Recommended | source |
| HAS (France) | 16 Dec 2020 | Re-assessment of SMR | SMR insufficient | source |
| ZIN (Netherlands) | 24 Nov 2016 | GVS-advies netupitant/palonosetron (Akynzeo®) voor de preventie van misselijkheid en braken bij matig of sterk emetogene… | advice published (GVS) | source |
| AWMSG (Wales) | 27 Jul 2016 | Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemothera… | recommended with restrictions (full) | source |
| G-BA (Germany) | 4 Feb 2016 | Akynzeo — benefit assessment §35a | added benefit: not proven | source |
3 further decisions for netupitant / palonosetron, across 3 agencies, are not shown here. They link to 2 further source documents.
Related molecules
- aprepitant — same ATC class A04A — Antiemetics
- ondansetron — same ATC class A04A — Antiemetics
- palonosetron — same ATC class A04A — Antiemetics
- granisetron — same ATC class A04A — Antiemetics
- fosaprepitant — same ATC class A04A — Antiemetics
- rituximab — also decided by HAS in 2020Q4
Coverage: 8 decisions for netupitant / palonosetron from 6 agencies, 2015 to 2023. Data to 7 Sep 2026. ATC class A04A — Antiemetics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.